dTIP leads collaboration in landmark AML treatment trial
At dTIP, we are proud to be a key partner in the RAPID trial, a ground-breaking initiative funded by PHRT to evaluate an ex-vivo drug testing platform developed by Snijder Lab, ETH Zurich. This trial approach, which aims to proof a (r)evolutionary treatment of acute myeloid leukaemia, has benefited from dTIP's extensive expertise.
dTIP's work went beyond the preparation and ethical submission of this randomized clinical intervention trial. Recognizing the importance of thorough groundwork, we guided the RAPID team in compiling the mandatory pre-requisites necessary to initiate a clinical performance study of an in vitro diagnostic device. This included a thorough assessment of the safety and performance of the device, defining its intended use, explaining its operating principles, and producing an investigator's brochure with a detailed risk assessment.
In addition, our advice was crucial in defining and creating a robust study protocol. We ensured that every aspect of the study was carefully planned, from setting up the study database to creating protocols for monitoring and data analysis. This comprehensive approach not only streamlined the study process, but also ensured that the highest standards of clinical research were maintained.
Despite the complexity of the study as a randomized in vitro diagnostic performance study, the initial feedback from the Ethics Committee in Zurich has been very encouraging.
Looking ahead, we at dTIP look forward to continuing to work closely with our partners. From obtaining final approval to conducting the trial, our commitment remains unwavering. Together, we are on the cusp of a new era in the treatment of acute myeloid leukaemia, demonstrating the power of collaboration to advance medical science.
For further information about the SNIJDER LAB please click external pagehere.